Tamsulosin Hydrochloride Capsule
NDC Package 57237-014-01
Package Information
Tamsulosin Hydrochloride capsules is are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [see Clinical Studies (14)]. This formulation utilizes a capsule delivery system. Marketed by Rising Pharma Holdings, Inc., this product is identified by NDC 57237-014 and is authorized under FDA application ANDA202433.
Identification & Billing
- RxCUI: 863669 - tamsulosin HCl 0.4 MG Oral Capsule
- RxCUI: 863669 - tamsulosin hydrochloride 0.4 MG Oral Capsule
- RxCUI: 863669 - tamsulosin HCl 0.4 MG Modified Release Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 57237 - Rising Pharma Holdings, Inc.
- 57237-014 - Tamsulosin Hydrochloride
- 57237-014-01 - 100 CAPSULE in 1 BOTTLE
- 57237-014 - Tamsulosin Hydrochloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (57237-014). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 57237-014-01 identifies a specific commercial package of 100 capsule in 1 bottle of Tamsulosin Hydrochloride, a human prescription drug labeled by Rising Pharma Holdings, Inc.. This capsule is formulated for oral use and contains tamsulosin hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Rising Pharma Holdings, Inc. on April 30, 2013. The current certification is valid through December 31, 2027.
How is this Rising Pharma Holdings, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 57237001401. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.